Free Trial
→ Financial legend: “This is bad, really bad...” (From Weiss Ratings) (Ad)tc pixel
NASDAQ:DARE

Dare Bioscience Q3 2026 Earnings Date & Estimates

Dare Bioscience logo
$0.72 -0.02 (-2.08%)
Closing price 04:00 PM Eastern
Extended Trading
$0.73 +0.01 (+0.75%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Dare Bioscience is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Dare Bioscience in Q3 2026

Dare Bioscience is expected to post earnings of -$0.14 per share on revenue of $2.02 million. In the same quarter a year earlier Dare Bioscience reported -$0.28 per share on revenue of $0.00 million. Dare Bioscience last reported on August 13, 2026, posting -$0.20 per share and beating the -$0.2967 consensus estimate. Dare Bioscience has beaten the consensus EPS estimate in 8 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.14
Expected Revenue
$2.02 million
Prior-Year EPS
-$0.28
Prior-Year Revenue
$0.00 million
Expected Revenue Growth
+89,113.1%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.20 (Beat by +$0.0967)
Last Quarter Revenue
$0.19 million
EPS Beat Rate
8 of last 8 quarters

Prepare for the Q3 2026 Call

Dare Bioscience Q3 2026 Earnings FAQ

Dare Bioscience (NASDAQ:DARE) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Dare Bioscience's Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Dare Bioscience to post earnings of -$0.14 per share for Q3 2026.

The consensus revenue estimate for Dare Bioscience is $2.02 million for Q3 2026.

Dare Bioscience Earnings Headlines

Daré Bioscience Launches CEO Corner Series To Update Investors On Women's Health Pipeline
October 13 at 2:03 PM  |  rttnews.comhttps://www.rttnews.com/3698578/dar-bioscience-launches-ceo-corner-series-to-update-investors-on-women-s-health-pipeline.aspx
Daré Bioscience Launches “CEO Corner” Video Series to Highlight the Company’s Pipeline of Women’s Health Innovations, Corporate Strategy and Opportunities
October 13 at 2:03 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/dar-bioscience-launches-ceo-corner-131500869.html
Elon Musk’s 4th Wealth Window Set to Open by October 30
Jeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He points to a new AI project tied to Musk's Cybercab reveal. Brown says Musk has opened major investment windows before, with PayPal, Tesla, and SpaceX marking milestones in tech history. He believes a fourth may open by October 30.tc pixel
October 16 at 1:00 AM  |  Brownstone Research (Ad)
Daré Bioscience Launches “CEO Corner” Video Series to Highlight the Company's Pipeline of Women's Health Innovations, Corporate Strategy and Opportunities
October 13 at 9:15 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/13/3379819/30757/en/dar%c3%a9-bioscience-launches-ceo-corner-video-series-to-highlight-the-company-s-pipeline-of-women-s-health-innovations-corporate-strategy-and-opportunities.html
Daré Bioscience Highlights 187-Fold Lower Sildenafil Exposure In Phase 1 Study
October 8, 2026  |  rttnews.comhttps://www.rttnews.com/3697644/dar-bioscience-highlights-187-fold-lower-sildenafil-exposure-in-phase-1-study.aspx
Daré Bioscience to Present Phase 1 Sildenafil Cream Data at Sexual Medicine Society of North America (SMSNA) Annual Fall Scientific Meeting
October 8, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/dar-bioscience-to-present-phase-1-sildenafil-cream-data-at-sexual-medicine-society-of-north-america-smsna-annual-fall-scientific-meeting-1036608760
See More Dare Bioscience Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Dare Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dare Bioscience and other key companies, straight to your email.

About Dare Bioscience

Daré Bioscience, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies designed to address women’s health needs. Its research programs span contraception, vaginal and reproductive health, fertility, pregnancy and postpartum care, and menopause.

The company’s lead commercial product, XACIATO (clindamycin phosphate) vaginal gel 2%, is an FDA-approved prescription treatment for bacterial vaginosis. Daré’s development pipeline has also included Ovaprene, a hormone-free monthly intravaginal contraceptive, and investigational candidates intended to address contraception, sexual health, vaginal conditions and hormone-related disorders.

Daré Bioscience is headquartered in San Diego, California, and conducts development activities through collaborations with biotechnology, pharmaceutical and academic partners. The company’s programs are primarily directed toward the U.S. market while seeking opportunities for broader international development and commercialization. Sabrina Martucci Johnson serves as the company’s president and chief executive officer.

View Dare Bioscience Profile
Earnings Tools